发布求助
文献互助 智能选刊 最新文献

Blood Reviews最新文献

筛选
英文 中文
Αlpha-thalassemia: A practical overview α-地中海贫血：实用概述
IF 7.4 2区 医学
Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101165
Khaled M. Musallam , M. Domenica Cappellini , Thomas D. Coates , Kevin H.M. Kuo , Hanny Al-Samkari , Sujit Sheth , Vip Viprakasit , Ali T. Taher
{"title":"Αlpha-thalassemia: A practical overview","authors":"Khaled M. Musallam ,&nbsp;M. Domenica Cappellini ,&nbsp;Thomas D. Coates ,&nbsp;Kevin H.M. Kuo ,&nbsp;Hanny Al-Samkari ,&nbsp;Sujit Sheth ,&nbsp;Vip Viprakasit ,&nbsp;Ali T. Taher","doi":"10.1016/j.blre.2023.101165","DOIUrl":"10.1016/j.blre.2023.101165","url":null,"abstract":"<div><p>α-Thalassemia is an inherited blood disorder characterized by decreased synthesis of α-globin chains that results in an imbalance of α and β globin and thus varying degrees of ineffective erythropoiesis, decreased red blood cell (RBC) survival, chronic hemolytic anemia, and subsequent comorbidities. Clinical presentation varies depending on the genotype, ranging from a silent or mild carrier state to severe, transfusion-dependent or lethal disease. Management of patients with α-thalassemia is primarily supportive, addressing either symptoms (eg, RBC transfusions for anemia), complications of the disease, or its transfusion-dependence (eg, chelation therapy for iron overload). Several novel therapies are also in development, including curative gene manipulation techniques and disease modifying agents that target ineffective erythropoiesis and chronic hemolytic anemia. This review of α-thalassemia and its various manifestations provides practical information for clinicians who practice beyond those regions where it is found with high frequency.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101165"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X23001352/pdfft?md5=bfdf3f2cb6cd0f3a1be7f480cd63530b&pid=1-s2.0-S0268960X23001352-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139092770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iron deficiency anemia among women: An issue of health equity 妇女缺铁性贫血:健康公平问题。
IF 7.4 2区 医学
Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101159
Grace H. Tang , Michelle Sholzberg
{"title":"Iron deficiency anemia among women: An issue of health equity","authors":"Grace H. Tang ,&nbsp;Michelle Sholzberg","doi":"10.1016/j.blre.2023.101159","DOIUrl":"10.1016/j.blre.2023.101159","url":null,"abstract":"<div><p><span>Iron deficiency<span><span> is the most common and widespread nutritional deficiency in the world. For women, the risk of iron deficiency and </span>iron deficiency anemia increases due to iron demands during pregnancy and regular iron losses due to menstruation during reproductive years. These interrelated conditions are of </span></span>public health<span><span> concern as they are highly prevalent, and the negative consequences such as chronic fatigue, cognitive impairment and poor </span>quality of life<span><span> are broad and multifaceted. People of low socioeconomic status are at higher risk of iron deficiency due to low intake of expensive iron-rich foods, and decreased access to healthcare. In this review, we applied a health equity lens to describe the current state of care for women with iron deficiency with or without anemia. We have highlighted several structural challenges that span from the laboratory diagnosis, inconsistent screening guidelines, and stigma associated with heavy menstrual bleeding, to </span>treatment barriers.</span></span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101159"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances 特发性多中心Castleman病:最新的诊断和治疗进展
IF 7.4 2区 医学
Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101161
Evan Lang , Frits van Rhee
{"title":"Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances","authors":"Evan Lang ,&nbsp;Frits van Rhee","doi":"10.1016/j.blre.2023.101161","DOIUrl":"10.1016/j.blre.2023.101161","url":null,"abstract":"<div><p>Idiopathic multicentric Castleman disease (iMCD) is a rare disease, and it is likely underdiagnosed because of the heterogeneity of clinical manifestations and laboratory findings. While the disease leads to significant morbidity and mortality, its causes are not yet fully elucidated. There have been significant advances in diagnosis and treatment of iMCD in the past decade, including the approval of the anti-IL-6 antibody siltuximab. In this review, we provide an update of the many new developments and publications surrounding iMCD.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101161"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X23001315/pdfft?md5=ccd844ecbcb062d737180f88229fb0ee&pid=1-s2.0-S0268960X23001315-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138541270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Richter's transformation: Transforming the clinical landscape 里克特的转变改变临床格局
IF 7.4 2区 医学
Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101163
A. Barrett , N. Appleby , H. Dreau , C.P. Fox , T. Munir , T.A. Eyre
{"title":"Richter's transformation: Transforming the clinical landscape","authors":"A. Barrett ,&nbsp;N. Appleby ,&nbsp;H. Dreau ,&nbsp;C.P. Fox ,&nbsp;T. Munir ,&nbsp;T.A. Eyre","doi":"10.1016/j.blre.2023.101163","DOIUrl":"10.1016/j.blre.2023.101163","url":null,"abstract":"<div><p><span><span><span>Richter transformation (RT) represents an aggressive histological transformation from </span>chronic lymphocytic leukaemia<span>, most often to a large B cell lymphoma. It is characterised by chemo-resistance and subsequent short survival. Drug development has struggled over recent years in light of the aggressive kinetics of the disease, lack of pivotal registrational trials and relative rarity of the phenomenon. In this review we will highlight the diagnostic and therapeutic challenges of managing patients with RT as well as taking a look to the future therapeutic landscape. Highly active </span></span>therapies<span> developed across B cell malignancies<span> are starting to impact this field, with T-cell activation therapies (CAR-T, bispecific antibodies), antibody-drug conjugates, and novel small molecule inhibitor combinations (</span></span></span><em>e.g.</em><span> BTKi-BCL2i) being actively studied. We will highlight the data supporting these developments and look to the studies to come to provide hope for patients suffering from this devastating disease.</span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101163"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138685608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management 免疫缺陷/失调-相关淋巴组织增生性疾病。修订分类和管理
IF 7.4 2区 医学
Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101167
Antonino Carbone , Amy Chadburn , Annunziata Gloghini , Emanuela Vaccher , Mark Bower
{"title":"Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management","authors":"Antonino Carbone ,&nbsp;Amy Chadburn ,&nbsp;Annunziata Gloghini ,&nbsp;Emanuela Vaccher ,&nbsp;Mark Bower","doi":"10.1016/j.blre.2023.101167","DOIUrl":"10.1016/j.blre.2023.101167","url":null,"abstract":"<div><p>Significant advances in the field of lymphoma have resulted in two recent classification proposals, the International Consensus Classification (ICC) and the 5th edition WHO. A few entities are categorized differently in the ICC compared to the WHO. Nowhere is this more apparent than the immunodeficiency lymphoproliferative disorders<span>. The three previous versions of the WHO classification (3rd, 4th and revised 4th editions) and the ICC focused on four clinical settings in which these lesions arise for primary categorization. In contrast the 2023 WHO 5th edition includes pathologic characteristics including morphology and viral status, in addition to clinical setting, as important information for lesion classification. In addition, the 2023 WHO recognizes a broader number of clinical scenarios in which these lesions arise, including not only traditional types of immune deficiency but also immune dysregulation<span>. With this classification it is hoped that new treatment strategies will be developed leading to better patient outcomes.</span></span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101167"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139104308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape 阵发性夜间血红蛋白尿:回顾患者的经验和治疗前景
IF 7.4 2区 医学
Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101158
Anem Waheed , Jamile Shammo , David Dingli
{"title":"Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape","authors":"Anem Waheed ,&nbsp;Jamile Shammo ,&nbsp;David Dingli","doi":"10.1016/j.blre.2023.101158","DOIUrl":"10.1016/j.blre.2023.101158","url":null,"abstract":"<div><p>Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder caused by complement-mediated hemolysis and thrombosis through the alternative pathway. The most common symptom of PNH is fatigue due to chronic anemia, which can negatively impact quality of life (QoL) and affect overall well-being. The currently approved therapies for PNH significantly limit intravascular hemolysis (IVH) and reduce the risk of thrombosis; however, they are associated with an infusion schedule that can become burdensome, and not all patients experience complete disease control. Several new complement inhibitors are in development that address the need for convenient routes of administration and aim to provide better disease control. With the variety of new treatment options on the horizon, hematologic markers as well as QoL concerns, patient opinion, and lifestyle factors should be considered to choose the optimal PNH treatment for each specific patient.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101158"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X23001285/pdfft?md5=0a811d3725af088dfae7b9baa97cfdf4&pid=1-s2.0-S0268960X23001285-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138541269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contemporary tools for evaluation of hemostasis in neonates. Where are we and where are we headed? 评价新生儿止血的现代工具。我们在哪里，我们要去哪里?
IF 7.4 2区 医学
Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101157
Rozeta Sokou , Stavroula Parastatidou , Aikaterini Konstantinidi , Andreas G. Tsantes , Nicoletta Iacovidou , Daniele Piovani , Stefanos Bonovas , Argirios E. Tsantes
{"title":"Contemporary tools for evaluation of hemostasis in neonates. Where are we and where are we headed?","authors":"Rozeta Sokou ,&nbsp;Stavroula Parastatidou ,&nbsp;Aikaterini Konstantinidi ,&nbsp;Andreas G. Tsantes ,&nbsp;Nicoletta Iacovidou ,&nbsp;Daniele Piovani ,&nbsp;Stefanos Bonovas ,&nbsp;Argirios E. Tsantes","doi":"10.1016/j.blre.2023.101157","DOIUrl":"10.1016/j.blre.2023.101157","url":null,"abstract":"<div><p><span>The assessment of hemostatic disorders<span><span><span> in neonates is crucial, but remains challenging for clinicians. Although the concept of developmental hemostasis<span> is widely accepted among hemostasis specialists globally, it is probably under-recognized by clinicians and laboratory practitioners. In parallel with age-dependent </span></span>hemostatic status maturation, comprehension of the differences between </span>normal values is crucial for the accurate diagnosis of potential hemorrhagic and thrombotic disorders of the vulnerable neonatal population. This review outlines the basics of developmental hemostasis and the features of the available </span></span>coagulation testing methods, with a focus on novel tools for evaluating the neonatal hemostatic profile. Common errors, issues, and pitfalls during the assessment of neonatal hemostasis are discussed, along with their impact on patient management. Current knowledge gaps and research areas are addressed. Further studying to improve our understanding of developmental hemostasis and its reflection on everyday clinical practice is warranted.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101157"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A 不折不扣的革命：新型延长半衰期第八因子替代产品和非替代制剂重塑了 A 型血友病的治疗格局
IF 7.4 2区 医学
Blood Reviews Pub Date : 2024-03-01 DOI: 10.1016/j.blre.2023.101164
Hussien Ahmed H. Abdelgawad , Rachel Foster , Mario Otto
{"title":"Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A","authors":"Hussien Ahmed H. Abdelgawad ,&nbsp;Rachel Foster ,&nbsp;Mario Otto","doi":"10.1016/j.blre.2023.101164","DOIUrl":"10.1016/j.blre.2023.101164","url":null,"abstract":"<div><p>Hemophilia A, an X-linked genetic disorder, is characterized by a deficiency or dysfunction of clotting Factor VIII. The treatment landscape has substantially changed by introducing novel extended half-life factor VIII (EHL-FVIII) replacement therapies such as efanesoctocog Alfa and non-factor replacement therapy such as emicizumab. These agents signal a shift from treatments requiring multiple weekly infusions to advanced therapies with long half-lives, offering superior protection against bleeding and improving patient adherence and quality of life. While EHL-FVIII treatment might lead to inhibitor development in some patients, non-factor replacement therapy carries thrombotic risks. Therefore, ongoing research and the generation of robust clinical evidence remain vital to guide the selection of optimal and cost-effective first-line therapies for hemophilia A patients.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"64 ","pages":"Article 101164"},"PeriodicalIF":7.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X23001340/pdfft?md5=fdc4f9b24ef41d865f0071c204b7d0ec&pid=1-s2.0-S0268960X23001340-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139030038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy? 通过抑制 E-选择素靶向血液恶性肿瘤：急性髓细胞性白血病治疗的甜蜜点？
IF 7.4 2区 医学
Blood Reviews Pub Date : 2024-02-28 DOI: 10.1016/j.blre.2024.101184
Geoffrey L. Uy , Daniel J. DeAngelo , Jay N. Lozier , Dennis M. Fisher , Brian A. Jonas , John L. Magnani , Pamela S. Becker , Hillard M. Lazarus , Ingrid G. Winkler
{"title":"Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?","authors":"Geoffrey L. Uy ,&nbsp;Daniel J. DeAngelo ,&nbsp;Jay N. Lozier ,&nbsp;Dennis M. Fisher ,&nbsp;Brian A. Jonas ,&nbsp;John L. Magnani ,&nbsp;Pamela S. Becker ,&nbsp;Hillard M. Lazarus ,&nbsp;Ingrid G. Winkler","doi":"10.1016/j.blre.2024.101184","DOIUrl":"10.1016/j.blre.2024.101184","url":null,"abstract":"<div><p>E-selectin, a cytoadhesive glycoprotein, is expressed on venular endothelial cells and mediates leukocyte localization to inflamed endothelium, the first step in inflammatory cell extravasation into tissue. Constitutive marrow endothelial E-selectin expression also supports bone marrow hematopoiesis via NF-κB-mediated signaling. Correspondingly, E-selectin interaction with E-selectin ligand (sialyl Lewis<sup>x</sup>) on acute myeloid leukemia (AML) cells leads to chemotherapy resistance in vivo. Uproleselan (GMI-1271) is a carbohydrate analog of sialyl Lewis<sup>x</sup> that blocks E-selectin binding. A Phase 2 trial of MEC chemotherapy combined with uproleselan for relapsed/refractory AML showed a median overall survival of 8.8 months and low (2%) rates of severe oral mucositis. Clinical trials seek to confirm activity in AML and mitigation of neutrophil-mediated adverse events (mucositis and diarrhea) after intensive chemotherapy. In this review we summarize E-selectin biology and the rationale for uproleselan in combination with other therapies for hematologic malignancies. We also describe uproleselan pharmacology and ongoing clinical trials.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"65 ","pages":"Article 101184"},"PeriodicalIF":7.4,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X24000171/pdfft?md5=6a37de75ade24871f4a8227183a16306&pid=1-s2.0-S0268960X24000171-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140141182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis 镰状细胞病术前输血的作用，系统回顾与荟萃分析
IF 7.4 2区 医学
Blood Reviews Pub Date : 2024-02-18 DOI: 10.1016/j.blre.2024.101183
Yasamin Abdu , Alaa Rahhal , Khalid Ahmed , Nada Adli , Mariam Abdou , Elrazi Awadelkarim Hamid Ali , Salam Al-Kindi , Mona Al Rasheed , Jaffer Altooq , Iheb Bougmiza , Mohamed A Yassin
{"title":"The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis","authors":"Yasamin Abdu ,&nbsp;Alaa Rahhal ,&nbsp;Khalid Ahmed ,&nbsp;Nada Adli ,&nbsp;Mariam Abdou ,&nbsp;Elrazi Awadelkarim Hamid Ali ,&nbsp;Salam Al-Kindi ,&nbsp;Mona Al Rasheed ,&nbsp;Jaffer Altooq ,&nbsp;Iheb Bougmiza ,&nbsp;Mohamed A Yassin","doi":"10.1016/j.blre.2024.101183","DOIUrl":"10.1016/j.blre.2024.101183","url":null,"abstract":"<div><p>This systematic review and meta-analysis aimed to provide guidance on preoperative blood transfusion strategies for patients with sickle cell disease (SCD). We included all randomized controlled and observational studies exploring the clinical outcomes of preoperative blood transfusion among patients with SCD compared to the conservative transfusion strategy until 14/09/2022.</p><p>Sixteen studies involving 3486 participants were analysed. The findings revealed a significantly higher bleeding rate in patients who received preoperative transfusion than those who followed a conservative strategy (RR = 4.32, 95% CI 1.75–10.68, <em>P</em> = 0.002, I2 = 0%). However, the two strategies had no significant differences in other clinical outcomes, such as acute chest syndrome, painful crisis, fever, neurological complications, thrombosis, ICU admission, and mortality. It is important to note that all the included studies had a moderate risk of bias. Preoperative transfusion in SCD was associated with a higher bleeding risk but a similar risk in other outcomes compared to conservative strategies. Notably, the increased bleeding risk observed seldom had clinical significance. We recommend individualizing management strategies, considering the overall positive impact of transfusions in reducing complications. Further high-quality studies are needed to refine recommendations.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"65 ","pages":"Article 101183"},"PeriodicalIF":7.4,"publicationDate":"2024-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X2400016X/pdfft?md5=dd69c17a7d33f03bd4c8da4aa597a962&pid=1-s2.0-S0268960X2400016X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139925876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信